NeuroCog Trials, Inc. announces that they have begun work supporting a pharmaceutical company clinical trial to assess cognition in patients with chronic kidney disease. The trial will examine the effects of
active drug treatment versus placebo on standard neuropsychological test outcomes. Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “We are tremendously excited to be a part of this program. Patients with chronic kidney disease can experience significant cognitive impairment due to the course of illness and the treatments they receive. Treatments that can improve this devastating component of the illness are sorely needed. Since cognitive assessment is new to many researchers conducting kidney disease trials, this is a brand new area of innovation. We feel that our reputation for dedication to science and data quality is gathering momentum across various medical disciplines. We are honored to be chosen to provide support for this trial.”
